HDAC2-miR183-5p epigenetic circuit contributes to the growth of Philadelphia chromosome–positive B cell acute lymphoblastic leukemia via PTEN/AKT and c-MYC signaling pathway
Journal of Leukocyte Biology · 2025
DOI: 10.1093/jleuko/qiae200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Yangyang Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui 230031, Chi…. Hauptthemen laut MEDLINE: MicroRNAs, Signal Transduction, Epigenesis, Genetic, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Science Foundation of China.
Abstract (Originalsprache)
Philadelphia chromosome-positive B cell acute lymphoblastic leukemia [Ph(+) B-ALL] is a hematological malignancy with a poor prognosis. Epigenetic abnormalities, especially abnormal histone acetylation and microRNA (miRNA) dysregulation, are a group of epigenetic patterns that contribute to leukemia progression. However, their regulatory mechanisms in Ph(+) B-ALL have not been fully elucidated. In this study, we identified that miR-183-5p is significantly downregulated in Ph(+) B-ALL and associated with poor prognosis. Moreover, we found that the BCR-ABL fusion gene is a key target gene of miR-183-5p. MiR-183-5p directly targets the BCR-ABL gene and induces cell apoptosis via PTEN/AKT and c-MYC signaling pathways. In addition, a histone deacetylase inhibitor could mitigate the suppressive effects of HDAC2 on miR-183-5p by promoting promoter acetylation, thereby enhancing cell apoptosis. In conclusion, our results indicate that miR-183-5p is a potential biomarker and suggest that a novel HDAC2-miR-183-5p epigenetic circuitry regulation may be involved in the pathogenesis of Ph(+) B-ALL. Taken together, These findings provide new insights into the design of promising molecular-targeted drugs for Ph(+) B-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Hematological Lab, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui 230031, China.
- Department of Interventional Radiology, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei, Anhui 230031, China.
- Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui 230031, China.
ORCID-Profile: Shudao Xiong
Förderung
- National Science Foundation of China
Zitieren
APA
Ding, Y., Feng, X., Liu, Z., Liao, Y., Pu, L., Liu, J., Wang, H., Zhai, Z., & Xiong, S. (2025). HDAC2-miR183-5p epigenetic circuit contributes to the growth of Philadelphia chromosome–positive B cell acute lymphoblastic leukemia via PTEN/AKT and c-MYC signaling pathway. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae200
Vancouver
Ding Y, Feng X, Liu Z, Liao Y, Pu L, Liu J, et al. HDAC2-miR183-5p epigenetic circuit contributes to the growth of Philadelphia chromosome–positive B cell acute lymphoblastic leukemia via PTEN/AKT and c-MYC signaling pathway. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiae200
BibTeX
@article{Ding2025,
author = {Ding, Yangyang and Feng, Xiangjiang and Liu, Zelin and Liao, Ya and Pu, Lianfang and Liu, Jun and Wang, Huiping and Zhai, Zhimin and Xiong, Shudao},
title = {HDAC2-miR183-5p epigenetic circuit contributes to the growth of Philadelphia chromosome–positive B cell acute lymphoblastic leukemia via PTEN/AKT and c-MYC signaling pathway},
journal = {Journal of Leukocyte Biology},
year = {2025},
doi = {10.1093/jleuko/qiae200}
}
EUVIMED